ReviewActa biochimica et biophysica Sinica2016
Identifying therapeutic targets in gastric cancer: the current status and future direction.
Review in Acta biochimica et biophysica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Mutational separation and clinical outcomes ofWorld journal of gastrointestinal surgery · 2023Article
- Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells.Oncology letters · 2021Article
- Long non-coding small nucleolar RNA host genes in digestive cancers.Cancer medicine · 2019Review
- CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer.Cancer science · 2018Article
- Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.Oncology letters · 2018Article
- Analysis of survival and prognosis of 298 gastric adenocarcinoma patients with no distant metastasis.Oncology letters · 2017Article
- YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression.International journal of oncology · 2017Article
- Article
- The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.Journal of genetics and genomics = Yi chuan xue bao · 2017Article
- GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.Oncotarget · 2017Article
- ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.